One time legal expenses were the reason. From the earnings press release for last quarter: "Legal expenses totaling $1,435 million related mainly to the additional $930 million provision for the settlement of the pantoprazole patent litigation and a $485 million provision relating to the modafinil antitrust litigation"
Thanks. If I add the 2.7 billions back in, the free cash flow is increasing. I noticed that they bought back over 1 billion dollars of shares. and the retained earning was increase. It is still growing based on the 5 year plan that they once promised.